- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: ABP 501.
Displaying page 1 of 1.
EudraCT Number: 2013-004654-13 | Sponsor Protocol Number: 20130258 | Start Date*: 2014-02-12 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: An Open-Label, Single-arm Extension Study to Evaluate the Long-term Safety and Efficacy of ABP 501 in Subjects with Moderate to Severe Rheumatoid Arthritis | |||||||||||||
Medical condition: Moderate to Severe Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) GB (Completed) ES (Completed) DE (Completed) BG (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000537-12 | Sponsor Protocol Number: 20120263 | Start Date*: 2013-09-25 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Phase 3, Multicenter, randomized, double-blind study evaluating the efficacy and safety of ABP 501 compared with Adalimumab in subjects with moderate to severe plaque psoriasis | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) PL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000525-31 | Sponsor Protocol Number: 20120262 | Start Date*: 2013-08-27 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects with Moderate to Severe Rheumatoid Arthritis | |||||||||||||
Medical condition: Moderate to Severe Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) CZ (Completed) ES (Completed) DE (Completed) HU (Completed) PL (Completed) BG (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000542-18 | Sponsor Protocol Number: 20200497 | Start Date*: 2021-12-21 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Multiple Switches Between Humira® (adalimumab [US]) and ABP 501 Compared With ... | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
